(Bloomberg) Michael Pearson and his company, Valeant Pharmaceuticals International Inc., were supposed to calm Wall Street doubters on Tuesday. Instead: chaos. What began before dawn with disappointing financial news quickly snowballed into the worst day in the drug company’s history, leaving investors wondering if Pearson, its controversial chief, can regain his grip.
After $600 Million Typo, Valeant CEO Is Back on the Hot Seat
This entry was posted in Syndicated. Bookmark the permalink.
